PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer
Abstract We aim to elucidate the prognostic value of PIK3CA mutations and copy number (CN) gain (PIK3CA-mut/gain) in hormone receptor-positive and HER2-negative (HR + /HER2−) breast cancer (BC). We analyzed primary HR + /HER2− BC from three publicly available datasets comprising over 2000 samples an...
Main Authors: | Ilenia Migliaccio, Marta Paoli, Emanuela Risi, Chiara Biagioni, Laura Biganzoli, Matteo Benelli, Luca Malorni |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-02-01
|
Series: | npj Breast Cancer |
Online Access: | https://doi.org/10.1038/s41523-022-00382-5 |
Similar Items
-
Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
by: Ilenia Migliaccio, et al.
Published: (2021-05-01) -
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
by: Lorenzo Rossi, et al.
Published: (2019-05-01) -
An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
by: Emanuela Risi, et al.
Published: (2019-12-01) -
Cell-Free DNA-Methylation-Based Methods and Applications in Oncology
by: Francesca Galardi, et al.
Published: (2020-12-01) -
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial
by: Francesca Galardi, et al.
Published: (2021-03-01)